Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Karolinska Development AB    KDEV   SE0002190926

KAROLINSKA DEVELOPMENT AB (KDEV)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Karolinska Development : Developments's portfolio company Modus Therapeutics recruits new Chief Medical Officer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 08:02am CET

STOCKHOLM - 14 September 2017. Karolinska Development's portfolio company Modus Therapeutics AB, which's drug candidate sevuparin is currently in a phase II study for treatment of patients with sickle cell disease, has recruited Professor Thomas Knittel as its new Chief Medical Officer (CMO).

Thomas Knittel (b. 1962), M.D., Ph.D. from University of Mainz with a speciality in internal medicine and medical gastroenterology and MBA from Kellogg School of Management/WHU, has more than 10 years of clinical experience from internal medicine and over 15 years of experience from research and development, medical affairs and marketing within the pharmaceutical industry.

Thomas Knittel formally took up his appointment at Modus Therapeutics in mid-August2017.

Further information and comments from Modus Therapeutics' CEO Ellen K Donnelly and Thomas Knittel are available at the link below: http://www.modustx.com/media/press-release/?y=2017

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: [email protected]

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KAROLINSKA DEVELOPMENT AB
02/15KAROLINSKA DEVELOPMENT : Q4 and 2017 Year-End Report - January-December
AQ
2017KAROLINSKA DEVELOPMENT : Chairman of the Board resigns from his position
AQ
2017KAROLINSKA DEVELOPMENT : BioArctic, a company in Karolinska Development's portfo..
GL
2017KAROLINSKA DEVELOPMENT : portfolio company Modus Therapeutics announces publicat..
GL
2017KAROLINSKA DEVELOPMENT : portfolio company Promimic receives FDA approval for HA..
GL
2017KAROLINSKA DEVELOPMENT : divests its holding in Lipidor
GL
2017KAROLINSKA DEVELOPMENT : announces outcome of the Extraordinary General Meeting
GL
2017KAROLINSKA DEVELOPMENT : Umecrine Cognition announces first patient included in ..
GL
2017KAROLINSKA DEVELOPMENT : will receive shares in Pharmanest AB
GL
2017KAROLINSKA DEVELOPMENT : realizes value increase in the portfolio company BioArc..
AQ
More news
Financials ( SEK)
Sales 2018 2,57 M
EBIT 2018 -33,8 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 140x
Capi. / Sales 2019 90,7x
Capitalization 358 M
Chart KAROLINSKA DEVELOPMENT AB
Duration : Period :
Karolinska Development AB Technical Analysis Chart | KDEV | SE0002190926 | 4-Traders
Technical analysis trends KAROLINSKA DEVELOPMENT AB
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 9,40  SEK
Spread / Average Target 65%
Managers
NameTitle
Viktor Drvota Chief Executive & Investment Officer
Hans Lennart Rudolf Wigzell Chairman
Fredrik Järrsten Chief Financial Officer
Vladimir Valeryevich Artamonov Independent Director
Henrijette Richter Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
KAROLINSKA DEVELOPMENT AB-2.96%45
MEDTRONIC PLC1.37%112 760
BAXTER INTERNATIONAL2.15%36 139
ZIMMER BIOMET HOLDINGS-2.46%24 394
ALIGN TECHNOLOGY10.87%20 165
HOYA CORPORATION-2.67%19 925